Impact of biologics on revision sinus surgery numbers in CRSwNP patients in a tertiary care center in Belgium.
This study aims to evaluate the impact of the reimbursement of biologics on the number of revision FESS procedures performed in a tertiary care center. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: An-sofie Viskens, Judith Adriaenssens, Elien Borgers, Peter Hellings Source Type: research
Ineligibility for Drug Reimbursement Implies Inferior Outcomes in Chronic Spontaneous Urticaria: A Hidden Source of Disparities
This study aims to outline the impact of treatment accessibility on CSU outcomes in the real world. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Hugo Mak, Valerie Chiang, Elsie Chan, Elaine Lee, Jackie Yim, Dorothy Lam, Philip Li Source Type: research
A Phase II study of LP-003, a novel high-affinity, long-acting anti-IgE antibody for allergic rhinitis
Allergic rhinitis (AR) is a common IgE-mediated disorder that affects large population worldwide. Omalizumab was the only approved anti-IgE antibody for several allergic diseases. However, due to Omalizumab's dosing regimen and high price, its application in AR is strictly limited. Thus, a new anti-IgE antibody with better efficacy, lower dosing, longer half-life and competitive pricing and compliance is worth to be investigated. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Xueyan Wang, Haiyun Shi, Ruowen Guo, Hongzhou Yang, Heng Liu, Lisha Li, Kai Guan Source Type: research
Impact of Patient Baseline Characteristics On Work Productivity and Activity Impairment Following Omalizumab Treatment In Patients With Allergic Asthma
The anti-IgE antibody omalizumab is effective for patients with moderate-to-severe allergic asthma, but the impact of baseline patient characteristics on work productivity and activity impairment is unclear. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Rohit Katial, Blaine Creasy, Pranil Raut, Hooman Pazwash, John Steinke, Lauren Millette, Monica Kraft Source Type: research
Impact Of Food Allergy On Work Productivity And Healthcare Resource Use In Patients With Allergic Asthma Treated With Omalizumab
Omalizumab is effective for the treatment of moderate-to-severe allergic asthma. However, the impact of comorbid food allergies (FA) on work productivity/activity impairment and healthcare resource use (HRU) in patients treated with omalizumab is unclear. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Panida Sriaroon, Ignacio Ansotegui, Alessandro Fiocchi, R. Sharon Chinthrajah, S. Shahzad Mustafa, Sachin Gupta, My Hanh Zacharia, Briana Cameron, Pranil Raut, David Fleischer Source Type: research
Peanut oral immunotherapy plus omalizumab for 24 weeks safely induced tolerance at 48 weeks in allergic adults
Peanut oral immunotherapy (POIT) with or without omalizumab can improve tolerance in children. Data on adults are limited. We evaluated the safety and efficacy of POIT, combined with omalizumab, over 48 weeks in adults. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Jacqueline Loprete, Jonathan Montemayor, Robyn Richardson, Jamie Rogers, Winnie Tong, Andrew Carr Source Type: research
Long –term safety of omalizumab in patients with severe asthma
Omalizumab is a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody that inhibits the binding of IgE to high-affinity receptors for allergic uncontrolled severe asthma. The primary objective of this study is to evaluate the long-term safety of Omalizumab in a real-world setting. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Maria Paixao, Itziar Eusebio, Maria G ómez Viciana, Cristina Juárez, Rocio Díaz-Campos, Consuelo Fernandez, Ismael G-Moguel, Jesus Crespo Source Type: research
Chronic spontaneous urticaria and autoimmunity: a retrospective study in a hospital in madrid
Recently, two mechanisms have been proposed to promote a potential autoimmune etiology of chronic spontaneous urticarial: type-I(autoallergic) and type-IIB(autoimmune). Aim:Knowing the autoimmunity profile of our patients and the response to Omalizumab(OMA). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Maria Luisa Qui ñones, Diana Pérez Alzate, Natalia Blanca López, Carlos Blanco Mota, Paula López González, Ana Prieto-Moreno Pfeifer, Francisco Javier Ruano Pérez Source Type: research
The Role Of Serum Biomarkers In Predicting Response To Omalizumab Therapy In Patients With Chronic Spontaneous Urticaria
This study investigated the real-world value of obtaining biomarkers to retrospectively predict responders and non-responders to this therapy. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Wesley Cain, Debajyoti Ghosh, Jonathan Bernstein Source Type: research
Management of severe chronic spontaneous urticaria with omalizumab
Omalizumab (OMA) is effective in chronic spontaneous urticaria (CSU), but some individuals do not respond to the standard dose (300 mg/month) or require treatment for a longer period (>6 months). We aimed to identify biomarkers predictive of the need for longer OMA treatment or for OMA updosing. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Laura Zubiaga Fernandez, Julia Rodriguez de Guzman Cejudo, Joan Bartra, Marta Ferrer, Maria Torres Jaen, Almudena Testera Montes, Carmen Rondon Segovia, Natalia Perez Sanchez, Ibon Eguiluz Source Type: research
The Disruptive Anti-IgE Molecule KIH_E07_79 Rapidly Desensitizes Allergic Effector Cells and Suppresses IgE Production in B-cells
Due to its key roles in the development and manifestation of allergic reactions, immunoglobulin E (IgE) has become an interesting molecular target. The monoclonal anti-IgE antibody omalizumab, which primarily inhibits IgE binding to its high-affinity receptor, Fc εRI⍺, on allergic effector cells has shown remarkable therapeutic success in various allergic indications. Recently, we have described an alternative anti-IgE molecule, termed KIH_E07_79, which in addition to the neutralization of free IgE rapidly disrupts pre-formed IgE-FcεRI complexes and ther eby stops pre-initiated systemic anaphylaxis in mice. (Source: Jo...
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Pascal Guntern, Luke Pennington, Daniel Brigger, Theodore Jardetzky, Alexander Eggel Source Type: research
"Assessing Xolair (Omalizumab) Utilization and Insurance Coverage Challenges in Idiopathic Urticaria: A Retrospective Analysis of Patient Outcomes and Prior Authorization Delays"
A cohort of 233 individuals from a private allergy& immunology practice was used to understand (1) the proportion of patients with urticaria who were prescribed Xolair; (2) the frequency of insurance coverage denials; and (3) the time between prior authorization (PA) submission and approval. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Annalina Sanfelici, Rachel Skelton, Anthony Szema Source Type: research
Dupilumab Improves Dermatology-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Inadequately Controlled with H1 Antihistamines
Chronic spontaneous urticaria (CSU) is characterized by wheals, angioedema, or both recurring for>6 weeks, affecting patients ’ quality of life (QoL). Here we report the effect of dupilumab on dermatology-specific QoL as measured by the Dermatology Life Quality Index (DLQI) in omalizumab-naïve CSU patients inadequately controlled with H1 antihistamines. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marcus Maurer, Thomas B. Casale, Lisa A. Beck, Sarbjit Saini, Moshe Ben-Shoshan, Gil Yosipovitch, J érôme Msihid, Philip Sugerman, Sonya Cyr, Ryan Thomas, Chien-Chia Chuang Source Type: research
Dupilumab Improves Urticaria-Specific Quality of Life in Patients with Chronic Spontaneous Urticaria Uncontrolled by H1 Antihistamines
Chronic spontaneous urticaria (CSU) negatively impacts patients ’ quality of life (QoL). The Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) captures physical, psychosocial, and practical domains of QoL in CSU patients. The current analysis evaluated the effect of dupilumab on CU-Q2oL items in omalizumab-naïve CSU patients inadequately controlled wi th H1 antihistamines. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Marcus Maurer, Thomas Casale, Gil Yosipovitch, Sarbjit Saini, Moshe Ben-Shoshan, Lisa Beck, J érôme Msihid, Philip Sugerman, Sonya Cyr, Ryan Thomas, Chien-Chia Chuang Source Type: research
Biologics for asthma and risk of pneumonia
CONCLUSIONS: Mepolizumab, omalizumab and benralizumab, but not dupilumab, were associated with high odds of reporting pneumonia. Our results represent only potential associations between these biologics and pneumonia but not causality. The nature of the FAERS database is such that the cause of the reported events is uncertain. Therefore, we can only roughly estimate the incidence of AEs by the signal strength (ROR value). Nevertheless, although causality could not be assessed, the signal from our study is interesting. We believe it deserves to be further substantiated by real-world studies with robust designs.PMID:38294705...
Source: Journal of Asthma - January 31, 2024 Category: Respiratory Medicine Authors: Maria Gabriella Matera Josuel Ora Luigino Calzetta Paola Rogliani Mario Cazzola Source Type: research
